Advertisement
Andexanet alfa can reverse the anticoagulant effects of factor Xa inhibitors

AHA: Andexanet Alfa Can Reverse Effect of Factor Xa Inhibitors

0
Reversal of anticoagulant activity of apixaban and rivaroxaban seen in older healthy participants
Patients with heart failure initiating mineralocorticoid receptor antagonists are rarely monitored in accordance with guidelines. The findings were published in the Nov. 10 issue of the Journal of the American Medical Association

AHA: Infrequent Monitoring for Heart Failure Patients on MRAs

0
Low monitoring rates in clinical practice in patients initiating mineralocorticoid receptor antagonists
Male and female cardiologists have different job activities and salaries

AHA: Gender Disparity in Cardiologists’ Salaries

0
Gender differences in compensation even after adjustment for measured characteristics
Individuals with central obesity but of normal weight according to body mass index have a higher risk of premature mortality than overweight or obese people

Central Obesity Is Hazardous, Even at a Normal Weight

0
Research suggests BMI insufficient for assessing health risks
Direct patient contracting practices

ACP Issues Guidance on ‘Concierge’ Practices

0
Growth of DPCPs fueled by physicians' frustration; may exacerbate disparities in health care
Patients with normal or near-normal coronary angiogram results at age 65 years or older have significantly longer survival than the general population

Normal Coronary Angiogram at 65 Predicts Survival

0
Death rate is lower than that of general population; rate of ischemic events also low
Macrolides are associated with a small but measurable increased risk of sudden cardiac death

Macrolides May Raise Cardiovascular Risks

0
Macrolides were linked to small, but significant, chances of sudden cardiac death
Women are less likely than men to get the recommended treatments for myocardial infarction survivors

AHA: Women More Often Receive Suboptimal Post-MI Care

0
This could explain gender gap in survival, researchers say
At least 16.8 million Americans could potentially benefit from the type of aggressive blood pressure treatment pursued under the Systolic Blood Pressure Intervention Trial (SPRINT). The findings were published online Nov. 9 in the New England Journal of Medicine to coincide with presentation at the annual meeting of the American Heart Association

AHA: Reducing Blood Pressure Target Could Increase Benefits

0
Risk of CVD was lowered by 25 percent, while all-cause mortality risk was reduced 27 percent
Combination therapy of endovascular revascularization and supervised exercise is associated with greater improvements than supervised exercise alone for patients with intermittent claudication. The findings were published in the Nov. 10 issue of the Journal of the American Medical Association

AHA: Combo Tx Ups Benefits in Intermittent Claudication

0
Greater improvements in waking distances, quality of life with revascularization plus exercise